RESUMEN
Odontogenic tumors occur within the jaw bones and may be derived from odontogenic epithelium or ectomesenchyme or contain active components of both tissue types. We investigated the gene expression profile of enamel matrix proteins (EMPs), genes related to osteogenesis, and the mineralization process in odontogenic tumor cell populations focusing on an ameloblastoma (AB-1), a keratocystic odontogenic tumor (KCOT-1), and a calcifying epithelial odontogenic tumor (CEOT-1). All cell populations were shown to be epithelial in origin by CK14 expression. All tested EMPs were expressed by all odontogenic tumor cell types, with higher transcript levels seen in the AB-1 population especially for AMEL, AMBN, and ODAM. CEOT-1 cell populations showed a greater content of ALP-positive cells as well as higher ALP mRNA levels. Using qRT-PCR, we found a higher expression of 8 genes in the CEOT-1 compared to the AB-1 and KCOT-1. In this study we demonstrated the establishment of AB-1, KCOT-1 and CEOT-1 cell populations. The unique gene expression profiles of AB-1, KCOT-1, and CEOT-1 cells and their interactions with the surrounding microenvironment may support their unique tumor development, progression, and survival.
Asunto(s)
Esmalte Dental/metabolismo , Esmalte Dental/patología , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Tumores Odontogénicos/genética , Osteogénesis/genética , Línea Celular Tumoral , Proliferación Celular , Forma de la Célula , Proteínas del Esmalte Dental/genética , Proteínas del Esmalte Dental/metabolismo , Humanos , Inmunohistoquímica , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Tumores Odontogénicos/patología , ARN Mensajero/genética , ARN Mensajero/metabolismoRESUMEN
Gene expression profiles of human ameloblastoma microdissected cells were characterized with the purpose of identifying genes and their protein products that could be targeted as diagnostic and prognostic markers as well as for potential therapeutic interventions. Five formalin-fixed, decalcified, paraffin-embedded samples of ameloblastoma were subjected to laser capture microdissection, linear mRNA amplification, and hybridization to oligonucleotide human 41,000 RNA arrays and compared with universal human reference RNA, to determine the gene expression signature. Assessment of the data by Significance Analysis of Microarrays (SAM) and cluster analysis showed that 38 genes were highly expressed (two-fold increase) in all samples, while 41 genes were underexpressed (two-fold reduction). Elements of the sonic hedgehog pathway and Wingless type MMTV integration site family were validated by immunohistochemistry. We have identified the expression of multiple genes and protein products that could serve as potential diagnostic, prognostic, and therapeutic targets.
Asunto(s)
Ameloblastoma/genética , Genómica/métodos , Amelogenina/genética , Biomarcadores de Tumor/genética , Calbindina 2 , Proteínas del Esmalte Dental/genética , Proteínas de la Matriz Extracelular , Perfilación de la Expresión Génica/métodos , Proteínas Hedgehog/genética , Humanos , Calicreínas/genética , Láseres de Semiconductores , Metaloproteinasa 20 de la Matriz/genética , Microdisección/métodos , Proteínas de Neoplasias/genética , Hibridación de Ácido Nucleico , Análisis de Secuencia por Matrices de Oligonucleótidos , Receptores Patched , Proteínas/genética , ARN Mensajero/genética , ARN Neoplásico/genética , Receptores de Superficie Celular/genética , Receptores Acoplados a Proteínas G/genética , Proteína G de Unión al Calcio S100/genética , Receptor Smoothened , Proteínas Wnt/genéticaRESUMEN
To determine whether a 3-week hepatitis B (HB) vaccination could achieve protective immunity, 89 healthy non-immunized young adults received three doses of 20 micrograms each of HBs antigen (GenHevac B, Pasteur) and were randomly assigned to schedule A (n = 44): two doses at day 0, one dose at day 21; or schedule B (n = 45): one dose at days 0, 10 and 21. Seroprotection rates (anti-HBs > or = 10 mIU ml-1) for groups A and B respectively were: 23 and 40% at day 21; and 77 and 91% at day 82 (not significant). Anti-HBs geometric mean titres were higher in group B than in group A (p < 0.05) at days 21 (6.4 versus 3.8) and 82 (77.6 versus 33.5). One year after primary vaccination, the seroprotection rate remained as high as 90% in the vaccinees of group B; after boosting all vaccinees had protective levels of anti-HBs antibodies. Thus 3-week HB vaccination with GenHevac B allowed early and durable protective immunity.